Poractant alfa versus bovine lipid extract surfactant: Prospective Comparative Effectiveness Study.

Poractant alfa versus bovine lipid extract surfactant: Prospective Comparative Effectiveness Study.  Lemyre B, Lacaze-Masmonteil T, Shah PS, Bodani J, Doucette S, Dunn M, et al. Journal of Perinatology. 2022;

Abstract

Objective: To compare short-term respiratory outcomes in preterm infants treated with bovine lipid extract surfactant or poractant alfa.

Study design: Prospective comparative effectiveness cohort study of infants <32 weeks’ gestational age requiring surfactant in thirteen centers. Each center provided bovine lipid extract surfactant for a set period of time in the year 2019 and then changed to poractant alfa for the remainder of the year. The primary outcome was total duration of respiratory support.

Result: 968 infants were included. 494 received bovine lipid extract surfactant and 474 received poractant alfa. No difference was observed in the total duration of respiratory support (mechanical ventilation or non-invasive) (median 38 vs 40.5 days), need to re-dose surfactant, bronchopulmonary dysplasia, survival to discharge, or length of admission.

Conclusion: In this pragmatic study, we did not identify any difference in short-term outcomes between the groups based on the type of surfactant received.

1. Lemyre B, Lacaze-Masmonteil T, Shah PS, Bodani J, Doucette S, Dunn M, et al. Poractant alfa versus bovine lipid extract surfactant: Prospective Comparative Effectiveness Study. Journal of Perinatology. 2022;

More information can be found here: https://pubmed.ncbi.nlm.nih.gov/35177795/